Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 1

Status

Recruiting 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 2Gastrointestinal 1

Conditions

Colorectal Neoplasms 23Pancreatic Neoplasms 10Colonic Neoplasms 8Stomach Neoplasms 7Esophageal Neoplasms 7Rectal Neoplasms 5Neoplasm Metastasis 5Carcinoma, Non-Small-Cell Lung 5Adenocarcinoma Of Esophagus 5Urinary Bladder Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Cholangiocarcinoma 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Ovarian Neoplasms 3Neoplasms 3Endometrial Neoplasms 3Adenocarcinoma 3Uterine Cervical Neoplasms 2Melanoma 2Lung Neoplasms 2Gastrointestinal Neoplasms 2Carcinoma, Hepatocellular 2Biliary Tract Neoplasms 2Urothelial Carcinoma of the Bladder 1Triple Negative Breast Neoplasms 1Tongue Neoplasms 1Thyroid Neoplasms 1Solid Tumors 1Small Bowel Adenocarcinoma 1Sarcoma, Ewing 1

Interventions

Oxaliplatin 3Leucovorin 3Fluorouracil 3Capecitabine 3zolbetuximab 2trastuzumab deruxtecan 2pembrolizumab 2Ramucirumab 2Paclitaxel 2repotrectinib 1lenvatinib 1fludarabine 1enzalutamide 1durvalumab 1darolutamide 1aldesleukin 1Vinorelbine 1Radiosurgery 1Radiation 1Prednisone 1Prednisolone 1Positron-Emission Tomography 1Pemetrexed 1PF06821497 1Nivolumab 1Negative-Pressure Wound Therapy 1Microscopy, Confocal 1MORAb-202 1Irinotecan 1Immunotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Adenocarcinoma × Fluorouracil × 30 days × Clear all
NCT06901531 2026-06-05

LUCERNA

Astellas Pharma Inc

Phase 3 Recruiting
500 enrolled
Tumor-Agnostic

Adenocarcinoma, Neoplasms

NCT05365581 2026-05-28

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

Astellas Pharma Inc

Phase 1 Recruiting
398 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT07431281 2026-05-27

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

AstraZeneca

Phase 3 Recruiting
2,130 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡